 |
|
Cardiac-Specific Troponin I Levels and Risk of Coronary Artery Disease and Graft Failure Following Heart Transplantation
Carlos A. Labarrere, MD;
David R. Nelson, MS;
Catherine J. Cox, MD;
Douglas Pitts, MD;
Philip Kirlin, MD;
Harold Halbrook, MD
JAMA. 2000;284:457-464.
Context Previous studies have yielded conflicting data regarding whether a relationship exists between elevated cardiac troponin levels and acute allograft rejection in patients who have received heart transplants.
Objective To determine whether cardiac troponin I levels after heart transplantation were associated with a procoagulant microvasculature and long-term allograft outcome.
Design Prospective cohort study with a mean (SE) follow-up of 45.1 (2.5) months. Serum troponin I levels were measured 9.9 (0.2) times per patient during the first 12 months after heart transplantation.
Setting Heart transplant center in the United States.
Patients A total of 110 consecutive patients who received a heart transplant between 1989 and 1997 and survived at least 1 year after transplantation.
Main Outcome Measures Histological and immunohistochemical biopsy findings, development of coronary artery disease (CAD), and graft failure in patients with vs without elevated serum cardiac troponin I levels.
Results All recipients had elevated troponin I levels during the first month after transplantation. Troponin I levels remained persistently elevated during the first 12 months in 56 patients (51%) and became undetectable in 54 patients (49%). Persistently elevated troponin I levels were associated with increasing fibrin deposits in microvasculature and cardiomyocytes (P<.001). Patients with persistently elevated levels of troponin I had significantly increased risk for subsequent development of CAD (odds ratio [OR], 4.3; 95% confidence interval [CI], 1.8-10.1; P<.001) and graft failure (OR, 3.4; 95% CI, 1.2-9.7; P = .02), and also developed more severe CAD (OR, 4.2; 95% CI, 1.9-9.3; P<.001) and showed more disease progression (OR, 3.7; 95% CI, 1.3-10.4; P = .009).
Conclusion In this study, elevated cardiac troponin I levels, which are considered to be a noninvasive surrogate marker of a procoagulant microvasculature, identified a subgroup of patients with high risk for developing CAD and graft failure after cardiac transplantation.
Author Affiliations: Methodist Research Institute (Dr Labarrere) and Transplant Center (Drs Pitts, Kirlin, and Halbrook) and Department of Pathology (Dr Cox), Clarian Health, Indianapolis, Ind; and Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio (Mr Nelson).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
July 26, 2000
JAMA. 2000;284(4):505-506.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cardiac Allograft Vasculopathy: Recent Developments
Schmauss and Weis
Circulation 2008;117:2131-2141.
ABSTRACT
| FULL TEXT
Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded
Jeremias and Gibson
ANN INTERN MED 2005;142:786-791.
ABSTRACT
| FULL TEXT
The impact of mode of donor brain death on cardiac allograft vasculopathy: An intravascular ultrasound study
Mehra et al.
J Am Coll Cardiol 2004;43:806-810.
ABSTRACT
| FULL TEXT
Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: A two-year outcome analysis
Khan et al.
J Am Coll Cardiol 2001;38:991-998.
ABSTRACT
| FULL TEXT
Is Troponin I Associated with Post-Transplant Risk for CAD and Graft Failure?
Journal Watch Cardiology 2000;2000:8-8.
FULL TEXT
|
